Notification Regarding Issuance of Unsecured Straight Bonds
Filed with TSE · · 2 pages · English
Watch Eisai's latest callEisai (Tokyo:4523) Q1 2027 Earnings Call · Replay · Aug 3Read the transcript of Eisai (Tokyo:4523) Q1 2027 Earnings CallEarlier from Eisai
- BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
- Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
- Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
- Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Later from Eisai
- Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
- Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference® 2026 (AAIC®)
- UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
- FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
Follow Eisai into a list and get an email when it puts out news.
Follow Eisai